Cassava Sciences | PTIE - Cash And Equivalent


Cassava Sciences reported $86.57M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
Cara Therapeutics USD 20.73M 684K Dec/2025
Cassava Sciences USD 86.57M 8.93M Mar/2026
Eisai JPY 301.65B 16.27B Sep/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Geron USD 68.9M 10.54M Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Novavax USD 228.36M 12.27M Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025